ALK-Abelló A/S has announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has approved EURneffy® 2 mg in the United Kingdom for the treatment of anaphylaxis in adults and children weighing 30 kg or more. This marks the first approval of a needle-free adrenaline nasal spray for emergency allergic reaction treatment in the UK. Expected to launch in the market once access negotiations conclude, EURneffy® offers a longer shelf life and superior temperature stability compared to existing adrenaline auto-injectors. The approval was based on data from a development program involving over 700 participants, with no serious adverse events reported. This innovative product aims to transform the management of severe allergies, making adrenaline administration more accessible and reliable.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.